ClinicalTrials.gg
CompletedNCT01848340Updated Nov 4, 2013

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

A Phase 1 interventional study of GSK1265744B (sodium salt) containing 14C-GSK1265744B and 150 mg GSK1265744B in HIV-associated Lipodystrophy Syndrome, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-11-04.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This will be a two-part study in healthy adults. Part A is a phase 1, non-randomized, open label, single-dose, single-centre mass balance study utilizing a radiolabeled dose to investigate the recovery, excretion, and pharmacokinetics of oral GSK1265744 in a cohort of 6 healthy adult male subjects. Subjects will undergo a pre-study screening visit within 30 days of the first dose and those who successfully pass pre-study assessments and meet eligibility criteria will be enrolled into the study to receive the equivalent of a 30 mg dose of GSK1265744 as an oral solution, containing approximately 70 microcuries (mcg Ci) [0.96 millisieverts (mSv)] of radioactivity under fasted conditions. Blood, urine and fecal samples will be collected for a maximum of 504 hours (21 days) following study drug administration. In Part B, approximately 10 healthy male and female subjects will be enrolled to evaluate the single-dose safety, tolerability and PK of supratherapeutic dose of GSK1265744 150 mg compared with placebo. Each subject will receive a single dose of GSK1265744 150 mg or placebo on Day 1 under fasting conditions in the morning. Blood, urine and fecal samples will be collected for 336 hours (14 days) following dosing.

02

Conditions studied

  • HIV-associated Lipodystrophy Syndrome

Keywords

  • mass balance
  • GSK1265744
  • supratherapeutic
  • integrase inhibitor
  • healthy volunteer
03

In context

HIV-Associated Lipodystrophy Syndrome

25 studies on the registry are indexed under HIV-Associated Lipodystrophy Syndrome; none are open to participants now.

This study's enrollment of 16 is below the median of 100 across 20 interventional studies indexed under HIV-Associated Lipodystrophy Syndrome.

Browse HIV-Associated Lipodystrophy Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • Part A: Male subjects between 30 and 55 years of age at the time of signing the .
  • Part B: Male or female between 18 and 60 years of age inclusive, at the time of signing the informed consent.
  • Parts A and B male subjects with female partners of must agree to use one of the methods listed in protocol. This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of study medication.
  • Part B: A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, bilateral salpingo-oophorectomy or hysterectomy; or defined as 12 months of spontaneous amenorrhea. Woman with child-bearing potential and is abstinent or agrees to use one of the contraception methods listed in protocol for an appropriate period of time prior to the start of dosing. Female subjects must agree to use contraception until 14 days after the last dose of study medication
  • (ALT), alkaline phosphatase (ALP) and \<= 1.5xUpper limit of normal () (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Body weight >= 50 kilogram (kg) and (BMI) within the range 18.5-31.0 kg/meter square (m\^2) (inclusive).
  • Capable of giving written informed consent
  • Part A only: Available to complete the study (maximum of 21 days confinement in the clinical research unit).
  • Part A only: A history of regular bowel movements (averaging one or more bowel movements per day).

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome).
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces [360 millilitre (mL)] of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor contraindicates their participation.
  • Part A only: Subjects who have received a total body radiation dose of greater than 5.0 mSv or exposure to significant radiation (e.g. serial X-ray or computerised topography (CT) scans, barium meal etc.) in the 12 months prior to this study.
  • Part A only: Any condition that could interfere with the accurate assessment and recovery of radioactivity [14C].
  • Part A only: Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months.
  • Part A only: Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy must be excluded.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • A positive test for (HIV) antibody.
  • Part B only: Pregnant or lactating females as determined by positive serum or urine Human Chorionic Gonadotropin (hCG) test at screening or prior to dosing.
  • The subject's systolic blood pressure is outside the range of 90-140 millimetre of mercury (mmHg), or diastolic blood pressure is outside the range of 45-90 mmHg.
  • History of cardiovascular disease including: Heart rate \<45 and >100 beats per minute in males and \<50 and >100 beats per minute in females. QRS duration >120 milliseconds (msec) and interval (QTc) interval B >450 msec in both males and females. Evidence of previous myocardial infarction, history/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease, any conduction abnormality [including but not specific to left or right complete bundle branch block, atrioventricular (AV) block [2nd degree (type II) or higher], Wolf Parkinson White [WPW] syndrome) or sinus pauses >3 seconds.
  • Any significant arrhythmia which, in the opinion of the principal Investigator and GSK Medical Monitor, will interfere with the safety for the individual subject. Nonsustained (>=3 consecutive ventricular ectopic beats) or sustained ventricular tachycardia
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part A: 14C-GSK1265744 Arm

    Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.

    Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B

  • Experimental
    Part B: GSK1265744 Arm

    In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg

    Drug: 150 mg GSK1265744B

  • Placebo comparator
    Part B: Placebo Arm

    In Part B - 2 subjects will be randomised to receive a single dose of placebo

    Drug: Placebo

Interventions

  • A white to slightly colored nonsterile crystalline powder for oral solution

  • This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet

  • DrugPlacebo

    Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet

06

What researchers measure

Primary outcomes

  1. Part A: Percent recovery of total radioactive [14C] GSK1265744 in urine and feces.

    Measurement of total radioactivity present in individual samples (plasma, urine, and feces) collected for a minimum of 336 hours (14 days) post dose up to a maximum of 504 hours (21 days).

    Time frame: Up to 21 days

  2. Part A: Composite of plasma GSK1265744 PK parameters to access total radioactivity in blood

    The PK parameters will include: Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a profile \[AUC (0-t)\], Area under the concentration-time curve from time zero (predose) extrapolated to infinite time \[AUC (0-infinity)\], Maximum observed concentration (Cmax), Time of occurrence of Cmax (tmax), Terminal phase elimination rate constant (lambda z), apparent terminal phase half-life (t1/2), and oral clearance (CL/F) of plasma GSK1265744 and total radioactivity in plasma and blood following single dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 288, 312 and 336 hours post dose.

  3. Part B: Number of participants with the use of concurrent medication as a measure of safety and tolerability

    Time frame: Up to 14 days

  4. Part B: Absolute values and changes over time of hematology as a measure of safety and tolerability.

    Time frame: Up to 14 days

  5. Part B: Absolute values and changes over time of clinical chemistry as a measure of safety and tolerability.

    Time frame: Up to 14 days

  6. Part B: Absolute values and changes over time of urinalysis as a measure of safety and tolerability.

    Time frame: Up to 14 days

  7. Part B: Absolute values and changes over time of vital signs as a measure of safety and tolerability.

    Time frame: Up to 14 days

  8. Part B: Absolute values and changes over time of ECG intervals and ECG rhythm as a measure of safety and tolerability.

    Time frame: Up to 14 days

  9. Part B: Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 14 days

  10. Part B: Composite of plasma GSK1265744 PK parameters

    Plasma GSK1265744PK parameters following a single-dose administration of 150 mg under fasted conditions will include: AUC (0-t)\], AUC (0-infinity), Cmax, tmax, lambda z, t1/2, and oral clearance (CL/F) of plasma

    Time frame: Up to 14 days

Secondary outcomes

  1. Part A: Blood: Plasma ratio of total drug-related material (radioactivity)

    The blood: plasma ratio of total radioactivity (Cb/Cp) will be calculated at each time point by Clinical Statistics at GSK.

    Time frame: Up to 21 days

  2. Part A: Percent of total radioactivity associated with red blood cells

    Percent of total radioactivity associated with red blood cells will be calculated based on radioactivity concentration in plasma and blood and hematocrit count.

    Time frame: Up to 21 days

  3. Part A: Absolute values and changes over time of hematology as a measure of safety and tolerability.

    Time frame: Up to 21 days

  4. Part A: Absolute values and changes over time of clinical chemistry as a measure of safety and tolerability.

    Time frame: Up to 21 days

  5. Part A: Absolute values and changes over time of urinalysis as a measure of safety and tolerability.

    Time frame: Up to 21 days

  6. Part A: Absolute values and changes over time of vital signs as a measure of safety and tolerability.

    Time frame: Up to 21 days

  7. Part A: Absolute values and changes over time of ECG intervals and ECG rhythm as a measure of safety and tolerability.

    Time frame: Up to 21 days

  8. Part A: Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 21 days

07

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2013
First posted
May 7, 2013
Start
May 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Nov 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01848340
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 7, 2013
Start date
May 2013
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Nov 4, 2013

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion